Image Place holder

Zeynep Eroglu, MD


Specialty: Medical Oncology
Program: Cutaneous Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Richard M. Schulze Family Foundation Outpatient Center at McKinley Campus
Overview

Cancer Types Treated: Basal Cell Carcinoma , Melanoma , Merkel Cell Carcinoma , Sarcoma

Dr. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials. Dr. Eroglu’s research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma. 

Education & Training

Board Certification:

  • Medical Oncology
  • Internal Medicine

Fellowship:

  • City of Hope/Harbor-UCLA Medical Center - Hematology/Oncology

Residency:

  • University of California, Irvine - Internal Medicine

Medical School:

  • UCLA David Geffen School of Medicine - MD
Participating Trials

CLINICAL TRIAL 18975
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Condition: Cutaneous
Intervention: REGN2810
Open

CLINICAL TRIAL 18992
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-033; TSR-042
Open

CLINICAL TRIAL 19127
A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients with Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination with Ipilimumab Followed by Nivolumab Monotherapy
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19441
Pilot Study of Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
Condition: Cutaneous
Intervention: Cobimetinib; Not Applicable; RO5185426 (Vemurafenib); Vemurafenib (Zelboraf)
Open

CLINICAL TRIAL 19485
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma
Condition: Cutaneous
Intervention: IMCgp100
Open

CLINICAL TRIAL 19475
Phase 2 Study of Ceritinib in Patients with Unresectable Melanoma
Condition: Cutaneous
Intervention: Ceritinib (Zykadia)
Open

CLINICAL TRIAL 19601
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986213; Nivolumab; Not Applicable
Open

CLINICAL TRIAL 18569
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma
Condition: Cutaneous
Intervention: Alkeran (Melphalan); DTIC (Dacarbazine); Dacarbazine; Ipilimumab; Melphalan; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18933
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Cutaneous
Intervention: Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19302
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an anti-LAG-3 Monoclonal Antibody, alone and in combination with an anti-PD-1 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: Not Applicable; TSR-033; TSR-042
Open

CLINICAL TRIAL 19396
A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma
Condition: Cutaneous
Intervention: IMO-2125; Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Nktr-214 And In combination With Nktr-214 Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); NKTR-214; NKTR-262; Nivolumab
Open

CLINICAL TRIAL 19634
Study of Resistance Mechanisms to Checkpoint Blockade
Condition: Cutaneous
Intervention:
Open

CLINICAL TRIAL 19327
A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases
Condition: Neurologic Oncology
Intervention: Avastin (Bevacizumab); Bevacizumab; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19407
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage IIIB/C Melanoma Patients
Condition: Cutaneous
Intervention: Daromun; Not Applicable
Open

CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19228
A Phase 2, Multi-Center, Open Label Study of NIR178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin lymphoma
Condition: Thoracic
Intervention: NIR178; Not Applicable; PDR001
Open

CLINICAL TRIAL 19686
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); BMS-986213; Nivolumab
Open

CLINICAL TRIAL 18989
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: PV-10; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 19495
A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases
Condition: Cutaneous
Intervention: Avelumab; MSB00100718C (Avelumab); Placebo
Open

CLINICAL TRIAL 19109
A Phase 1/2, Open-Label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab and Other Anti-Cancer Therapies in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); NKTR-214; Nivolumab
Open

CLINICAL TRIAL 18345
A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients with Advanced Solid Tumors
Condition: Genitourinary
Intervention: MK-3475 (Keytruda); Ziv-aflibercept
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma. Clin Cancer Res. 2018 Nov;24(22):5516-5524. Pubmedid: 29674508. Pmcid: PMC6195480.
  • Kugel CH, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res. 2018 Nov;24(21):5347-5356. Pubmedid: 29898988.
  • Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2018 Mar;36(7):667-673. Pubmedid: 28991513.
  • Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar;8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
  • Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 Jan;29(1):250-255. Pubmedid: 29045547. Pmcid: PMC5834131.
  • Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A. High response rate to PD-1 blockade in desmoplastic melanomas. Nature. 2018 Jan;553(7688):347-350. Pubmedid: 29320474. Pmcid: PMC5773412.
  • Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec;4(12):1721-1728. Pubmedid: 30242316.
  • Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM. Ceritinib Enhances the Efficacy of Trametinib in -Wild-Type Melanoma Cell Lines. Mol Cancer Ther. 2018 01;17(1):73-83. Pubmedid: 29133622. Pmcid: PMC5752595.
  • Wang DY, Eroglu Z, Ozgun A, Leger PD, Zhao S, Ye F, Luke JJ, Joseph RW, Haq R, Ott PA, Hodi FS, Sosman J, Johnson DB, Buchbinder EL. Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. Cancer Immunol Res. 2017 05;5(5):357-362. Pubmedid: 28396509. Pmcid: PMC5502536.
  • Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017 04;75:47-55. Pubmedid: 28214657.
  • Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, Klein O, Hassel JC, Sosman JA, Guminski A, Sullivan RJ, Ribas A, Carlino MS, Davies MA, Sandhu SK, Long GV. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017 02;28(2):368-376. Pubmedid: 27687304.
  • Kim DW, Zager JS, Eroglu Z. Improving clinical outcomes with pembrolizumab in patients with advanced melanoma. Chin Clin Oncol. 2017 02;6(1):2. Pubmedid: 28285535.
  • Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer. 2017;5:8. Pubmedid: 28239462. Pmcid: PMC5319013.
  • Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Sep;537(7619):254. Pubmedid: 27383789.
  • Shoushtari AN, Munhoz RR, Kuk D, Ott PA, Johnson DB, Tsai KK, Rapisuwon S, Eroglu Z, Sullivan RJ, Luke JJ, Gangadhar TC, Salama AK, Clark V, Burias C, Puzanov I, Atkins MB, Algazi AP, Ribas A, Wolchok JD, Postow MA. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer. 2016 Nov;122(21):3354-3362. Pubmedid: 27533633. Pmcid: PMC5134420.
  • Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016 Nov;122(21):3344-3353. Pubmedid: 27533448. Pmcid: PMC5767160.
  • Eroglu Z, Smalley KS, Sondak VK. Improving patient outcomes to targeted therapies in melanoma. Expert Rev Anticancer Ther. 2016 Jun;16(6):633-641. Pubmedid: 27137746.
  • Eroglu Z, Ribas A. Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. Ther Adv Med Oncol. 2016 Jan;8(1):48-56. Pubmedid: 26753005. Pmcid: PMC4699264.
  • Smalley KS, Eroglu Z, Sondak VK. Combination Therapies for Melanoma: A New Standard of Care?. Am J Clin Dermatol. 2016 Apr;17(2):99-105. Pubmedid: 26860106. Pmcid: PMC4805442.
  • Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, Meeth K, Tang HY, Yin X, Wood WH, Lehrmann E, Becker KG, Flaherty KT, Frederick DT, Wargo JA, Cooper ZA, Tetzlaff MT, Hudgens C, Aird KM, Zhang R, Xu X, Liu Q, Bartlett E, Karakousis G, Eroglu Z, Lo RS, Chan M, Menzies AM, Long GV, Johnson DB, Sosman J, Schilling B, Schadendorf D, Speicher DW, Bosenberg M, Ribas A, Weeraratna AT. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. 2016 Apr;532(7598):250-254. Pubmedid: 27042933. Pmcid: PMC4833579.
  • Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko J, Higham C, Puzanov I, Patel SP, Sosman JA, Woodman SE. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. Pigment Cell Melanoma Res. 2016 07;29(4):470-473. Pubmedid: 27089234. Pmcid: PMC5678944.
  • Kanz BA, Pollack MH, Johnpulle R, Puzanov I, Horn L, Morgans A, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB. Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer. 2016;4:60. Pubmedid: 27777770. Pmcid: PMC5067899.
  • Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016;4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
  • Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov;51(17):2689-2697. Pubmedid: 26364516. Pmcid: PMC4821004.
  • Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer. 2015 Dec;51(18):2792-2799. Pubmedid: 26608120. Pmcid: PMC4666799.
  • Yadav S, Sehrawat A, Eroglu Z, Somlo G, Hickey R, Yadav S, Liu X, Awasthi YC, Awasthi S. Role of SMC1 in overcoming drug resistance in triple negative breast cancer. PLoS One. 2014 Jan;8(5):e64338. Pubmedid: 23717600. Pmcid: PMC3661439.
  • Eroglu Z, Tagawa T, Somlo G. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. Oncologist. 2014 Feb;19(2):135-150. Pubmedid: 24436312. Pmcid: PMC3926785.
  • Eroglu Z, Fruehauf JP. A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemother Pharmacol. 2013 Jul;72(1):263-267. Pubmedid: 23636451.
  • Eroglu Z, Fielder O, Somlo G. Analysis of circulating tumor cells in breast cancer. J Natl Compr Canc Ne. 2013 Aug;11(8):977-985. Pubmedid: 23946176. Pmcid: PMC4159355.
  • Eroglu Z, Kong KM, Jakowatz JG, Samlowski W, Fruehauf JP. Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. Cancer Chemother Pharmacol. 2011 Oct;68(4):1081-1087. Pubmedid: 21769667. Pmcid: PMC3180631.